# Alterations in the plasma metabolome associated with maternal

- smoking during the first trimester
- 3 Wadzanai Masvosva <sup>1</sup>, Taija Voutilainen <sup>1</sup>, Marko Lehtonen <sup>1</sup>, Retu Haikonen <sup>2</sup>, Seppo
- Auriola <sup>1</sup>, Leea Keski-Nisula <sup>3,4</sup>, Jaana Rysä <sup>1</sup>, Olli Kärkkäinen <sup>1</sup>
- 

# Affiliations:

- 7 <sup>1</sup> School of Pharmacy, University of Eastern Finland
- 8 <sup>2</sup>Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio,
- Finland
- 10 <sup>3</sup>Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Finland
- 11 <sup>4</sup>Department of Obstetrics and Gynecology, Kuopio University Hospital, Finland

- **Correspondence:** Dr. Olli Kärkkäinen, School of Pharmacy, University of Eastern Finland,
- Yliopistonrinne 3, 70210 Kuopio, Finland; [olli.karkkainen@uef.fi](mailto:olli.karkkainen@uef.fi)

# **Plain language summary**

- Tobacco smoking during pregnancy has been associated with an increased risk of adverse
- outcomes like low birth weight. In this study, we measured changes in the circulating
- metabolome linked to maternal smoking in the first trimester and correlated these
- changes to the growth of the fetus. Maternal smoking during the first trimester of
- pregnancy was associated with an altered metabolite profile linked to endocrine disruption
- and increased oxidative stress. Furthermore, some these changes were associated with
- reduced growth of the fetus.

### **Abstract**

 Tobacco smoking during pregnancy has been associated with an increased risk of adverse outcomes like low birth weight. This study determined changes in the circulating metabolome linked to maternal smoking in the first trimester and correlated these changes to the growth of the fetus. The circulating metabolome was examined from first trimester plasma samples by non-targeted liquid chromatography mass spectrometry based metabolite profiling of 227 pregnant women (99 smokers and 117 non-smokers) from the Kuopio Birth Cohort Study. Tobacco smoking was self-reported through a questionnaire and verified with cotinine measurements from plasma samples. In summary, 64 significant differences were observed between the groups after correction for multiple testing e.g. in metabolites indicating endocrine disruption (e.g., dehydroepiandrosterone sulfate [DHEA-S], VIP=2.70, d=0.68, p<0.0001), metabolites associated with oxidative stress (e.g., bilirubin, VIP=2.00, d=0.50, p<0.0001) and lipid metabolism (e.g., LysoPC 16:1, VIP=2.07, d=0.51, p<0.0001). Some of these metabolites, e.g., DHEA-S and bilirubin, correlated with low birth weight, and some, e.g. LysoPC 16:1, correlated with small head circumference at birth. In conclusion, maternal smoking during the first trimester of pregnancy was associated with an altered metabolite profile linked to endocrine disruption and increased oxidative stress.

**Keywords:** tobacco, smoking, pregnancy, metabolome, metabolomics

# **Introduction**

 Smoking has been recognized as the most important preventable cause of mortality in the  $\cdot$  world<sup>1</sup>. Approximately 10% of women worldwide smoke during pregnancy, although the  $\parallel$  rate varies greatly between regions and countries<sup>2</sup>. Smoking during pregnancy exposes the fetus to the harmful effects of tobacco.

 Nicotine is the main psychoactive ingredient in tobacco, and it can easily cross the placental barrier. Nicotine concentrations in fetal circulation have been reported to be even 15% 53 higher than those detected in the maternal circulation<sup>3</sup>. Nicotine causes a general constriction of blood vessels, decreasing the delivery of nutrients to the developing fetus. Carbon monoxide is another harmful chemical present in tobacco smoking; it binds avidly to hemoglobin and subsequently reduces the amount of oxygen being carried to the fetus 57 thus increasing the risk for hypoxia<sup>4</sup>. During pregnancy, even low levels of tobacco smoking 58 have been associated with an increased risk of adverse outcomes like low birth weight<sup>5</sup>, 59 sudden infant death syndrome<sup>6</sup>, behavioral and neurodevelopmental impairments<sup>7</sup> and 60 asthma and obesity<sup>8</sup>. The effects of maternal tobacco smoking during pregnancy may be permanent and not just be evident from childhood but also last into adulthood, for example, leading to elevated blood pressure, endothelial dysfunction, and even changes in 63 renal structure<sup>9</sup>.





 The cohort consists of women from Finnish Northern Savo county expected to have delivery at KUH. The participants were recruited during their first trimester routine antenatal visit by a health care nurse, during weeks 6-9 of gestation mainly from the



This led to the selection of two study groups: a control group with 117 samples of women

who had not smoked during pregnancy and a study group with 99 samples of women who



# 143 Non-targeted LC-MS based metabolite profiling

 The metabolomics analysis was performed according to previously released guidelines with some modifications<sup>19</sup>. In brief, sample preparation was done by thawing plasma samples in ice-cold water; the samples were maintained in ice-cold water during all waiting periods before they were transferred for sample preparation into 96 well plates (Thermo Scientific



HILIC chromatographic set-up used an Acquity BEH amide column, Mobile phase A: 50%

Acetonitrile + 20 mM ammonium formate buffer, B: 90 % acetonitrile + 20 mM ammonium

- formate buffer, 12.5 min gradient, 0,6 ml/min.
- Both negative and positive electrospray ionization (ESI) were used in both analytical modes.
- ESI settings were ray voltage 3.5 kV for positive and 3.0 kV for negative, max spray current
- 100, flow rates 40 for sheath gas, 10 for auxiliary gas, and 2 for spare gas (as arbitrary units
- 175 for ion source), S-lens RF level 50 V, capillary and probe heater temperature 300 °C. A full
- scan range from m/z 60 to 700 in the HILIC modes and 120 to 1200 in the RP modes with a
- resolution of 70 000 (m/Δm, full width at half maximum at 200 u) and an automated
- injection time and gain control targeted at 1 000 000 ions. In the tandem mass

spectrometry (MS/MS), three peaks with apex triggers ranging from 0.2 up to 3 s were

selected for MS/MS fragmentation with 15 s dynamic exclusion. A normalized collision

energy at 20, 30, and 40%, was used in MS/MS with a mass resolution of 17 500 (m/Δm, full

width at half maximum at 200 u), an automated gain targeted at 50 000, and an isolation

window of 1.5 m/z.

 Data analysis was done using MS-dial software 4.90 version for peak picking, peak alignment, and metabolite identification. Data collection had an MS1 tolerance of 0.005 and an MS2 tolerance of 0.025. The retention time for parameters started at 0.5 minutes and stopped at 100 minutes with a mass range and MS/MS mass range of 50 Da up to 2000 Da. Peak detection parameters had a minimum peak height of 300,000 with an amplitude smoothing level of 3 scans, minimum peak width of 8 scans, and a mass slice width of 0.1 Da. Deconvolution parameters had a sigma window value of 0.5 with 0 as the amplitude



standards from the in-house library. Level 2 identification comprised putatively annotated

- compounds, identified by matching to exact mass and MS2 spectra against public libraries.
- Level 3 identification referred to the compounds identified at the chemical group level but
- lacking an exact compound identification, while level 4 consisted of unknown compounds.

#### 213 Statistical analysis.

 Differences between background characteristics were evaluated with Welch's t-test and  $\degree$  Chi<sup>2</sup> test. With respect to the metabolomics data, univariate analysis was done with Cohen's d effect sizes with p-values being calculated using Welch's t-test. Since molecular features in metabolomics analysis are not independent, the number of principal components needed to explain 95% of the variance in the metabolomics data in the principal component analysis (PCA) was used and to account for multiple testing the Bonferroni method was applied. Here, 184 PCs were needed to explain 95% of the variation in the 221 metabolomics data, therefore the  $\alpha$  level was adjusted to 0.0003. Findings with p-values between 0.05 and 0.0003 were considered to be trends. Additionally, we used partial-least- squares discriminant analysis (PLS-DA) to identify the variables that contributed most extensively to the variation between smoking and nonsmoking pregnant women in a multivariate analysis. Cross-validation was done by splitting the dataset into 7 subsets. Variable importance to the projection (VIP) values from PLS-DA are reported for each variable. Correlations between molecular features and birth weight or head circumference were calculated using linear regression. We used SIMCA 17.0 for multivariate data analysis solution, whereas we utilized the notame (version 0.3.0) R-package for the calculation of 230 univariate statistics for metabolomics data<sup>19</sup>. JASP (version 0.17) software was used to 231 calculate statistics related to the background characteristics between the non-smoking and smoking groups. Figures were made using Prism (GraphPad software Inc. version 10.0) and SIMCA version 17.0.

# 234 **Results**

- 235 The characteristics of the pregnant women and their newborns women are shown in Table
- 236 1. Smokers had a significantly lower parity, higher BMI values, pre-pregnancy weights and
- 237 were less likely to be in a relationship when compared to the nonsmoking controls. On
- 238 average, the newborns of smokers had a lower birth weight and head circumference when
- 239 compared to control newborns. Furthermore, they needed more antibiotic therapy and
- 240 treatment in the intensive care unit than the controls.
- 241
- 242
- 243 **Table 1:** Background characteristics of the study women.





244 Legend: <sup>a</sup> Welch's t test; <sup>b</sup> Chi<sup>2</sup> test.

245



 The correlation analysis indicated that birth weight was also positively associated with the 266 levels of biliverdin (r = 0.20, p = 0.0029), creatine (r = 0.15, p = 0.0029) and PC38:6

- 267 (16:0\_22:6) ( $r = 0.14$ ,  $p = 0.0035$ ) and negatively associated with those of cotinine ( $r = -0.18$ ,
- 268 p = 0.00096), Asp-Phe (r-0.15, p = 0.0026), DHEA-S (r = -0.15, p = 0.0265) and AC14:1 (r =-
- 269 0,13, p = 0.0049). Head circumference was negatively associated with the levels of 7a-
- 270 hydroxy-3-oxo-4-cholestenoic acid (r = -0.18, p=0.001), cotinine (r = -0.17,p=0.0013), LysoPC
- 271 16:1 (16:1/0:0) (r = -0.16, p = 0.0019), LysoPC 16:1 (0:0/16:1) (r = -0.15, p = 0.0028), AC 06:0 (r
- 272  $= -0.15$ ,  $p = 0.0037$ ) and lenticin ( $r = -0.14$ ,  $p = 0.0043$ ). These results are shown graphically
- 273 in Figure 3 and Figure 4.



**Figure 1:** Overview of metabolite profiling from the first trimester maternal plasma

samples. A total of 9600 molecular features were observed from the chosen samples. Panel

**A** shows the outcomes of the principal component analysis (PCA). A total of 184

components were needed to account for 95% of the variance in the data. PC1 (t1) explained

4.5 % of the variation in the data, and PC2 (t2) explained 4.3% of the data. Panel **B** shows

partial least squares discriminant analysis (PLS-DA) which illustrates the good separation

between the study groups (6 components, cum R2Y = 0.99, Q2 = 0.70). Panel **C** shows the p

values (Welch's t-test), Cohen's d effect sizes, and VIP values from the PLS-DA) of all of the

relevant molecular features. A total of 193 molecular features were significantly altered

 between the smokers' and nonsmokers' samples (adjusted α level= 0.0003, Bonferroni's correction).



**Figure 2:** Smokers show altered metabolite profile in the firsttrimester plasma samples when compared to nonsmoking controls. Box plots with whiskers (min and max) are shown with pvalue from a Welch's t-test (multiple testing adjusted α level was 0.0003). Biliverdin result should be considered a trend. Abbreviations: DHEA-S, dehydroepiandrosterone sulfate; PC, phosphatidylcholine.



 **Figure 3:** Association between the birth weight of the newborn and metabolite levels in the first trimester of pregnancy. Three metabolites were positively associated with birth weight

- and four were negatively associated with birth weight. Abbreviations: AC 14.1:
- tetradecenoylcarnitine; Asp\_Phe: Aspartyl-phenylalanine; PC: phosphatidylcholine; p: p-
- value, r: Pearson correlation coefficient



**Figure 4:** Correlations between the head circumference of the newborn and first trimester

- levels of metabolites. Six metabolites were negatively associated with differences in the
- head circumference between the groups. Abbreviations: AC 06:0, Hexanoylcarnitine;
- LysoPC: lysophosphatidylcholine, p: p-value, r: Pearson correlation coefficient

### **Discussion**

![](_page_19_Picture_219.jpeg)

 We found that pregnant women who were smokers had high levels of DHEA-S in the first trimester plasma samples, and that these were further associated with the lower birth 320 weight. DHEA-S is as a metabolic intermediate in the biosynthesis of sex steroids  $^{23}$ . Smoking has been shown to influence adrenal hormone production by upregulating the adrenal β-arrestin 1 enzyme, which is involved in the development of hyperaldosteronism 323 and consequently to higher basal levels of DHEA- $S^{24,25}$ . The elevated DHEA-S levels are evidence of an endocrine disorder attributable to maternal smoking and it has been

 reported that endocrine disturbances can be linked to growth retardation and neurological 326 impairments in the newborn<sup>26</sup>.

![](_page_20_Picture_219.jpeg)

![](_page_21_Picture_215.jpeg)

 Moreover, the metabolomics analysis also showed that the levels of three metabolites linked to tobacco smoking, namely nicotine, cotinine, 3-hydroxypyridine, were significantly increased in blood samples of the tobacco-exposed mothers. Here, cotinine exhibited a significant negative correlation to birth weight and head circumference. Interestingly, previous studies have shown that the metabolism of nicotine is accelerated during pregnancy; this was assessed by measuring the nicotine metabolite ratio at different 360 gestational weeks.

 Furthermore, the observed high levels of metabolites associated with caffeinated products (caffeine, theophylline, paraxanthine and trigonelline) are in line with previous studies that found that smoking pregnant women consume more caffeinated products compared to 365 their nonsmoking pregnant counterparts<sup>37</sup>. It is recognized that the metabolism of 366 compounds present in coffee is reduced during pregnancy<sup>38</sup>, and additionally, after

![](_page_22_Picture_217.jpeg)

379 The limitations of the current study include the self-reported use of tobacco smoking by the pregnant women. Although we had access to nicotine and cotinine levels which made it possible to detect current users, there might be some cases of pregnant women who were infrequent smokers as the blood samples were taken as a part of routine visits during the first trimester. We also observed some limitations of self-reporting, i.e., there were 7 controls that had to be excluded from the study because of high cotinine levels in these samples. Another limitation is the sample size, which was relatively small and limited the statistical power. For example, with a higher sample size, differences in the levels of sterols

![](_page_23_Picture_158.jpeg)

### **Acknowledgements**

![](_page_24_Picture_146.jpeg)

- VAURAS project, and the Finnish Foundation for Alcohol Studies. This paper belongs to the
- studies carried out by the Kuopio Birth Cohort consortium (www. KuBiCo.fi) and we thank
- our colleagues who are responsible for the design and conduct of the KuBiCo. We want to
- thank Essi Järvelä for assistance with sample collection, Miia Reponen and Juulia Kuparinen
- for technical assistance with the mass spectrometry analyses, Ewen MacDonald for proof-
- reading, and the staff of the Department of Obstetrics and Gynecology in Kuopio University
- Hospital. The authors also want to thank Biocenter Finland and Biocenter Kuopio for
- supporting the core LC-MS laboratory facility.

### **Conflict of interest**

- O.K. is a co-founder of Afekta Technologies Ltd. a company providing metabolomics
- analysis services. W.M, T.V, M.L, R.H, S.A, L.K-N, J.R declare no conflicts of interest.

#### **Data Sharing Statement**

420 The data that support the findings of this study are available on request from the corresponding author, OK. The study plan approved by the ethical committee and the participant consent terms preclude public sharing of these sensitive data, even in anonymized form.

#### References

- 1. Reitan T, Callinan S. Changes in Smoking Rates Among Pregnant Women and the General Female Population in Australia, Finland, Norway, and Sweden. *Nicotine Tob Res*. 2017;19(3):282-289. doi:10.1093/ntr/ntw188
- 2. Havard A, Chandran JJ, Oei JL. Tobacco use during pregnancy. *Addiction*. 2022;117(6):1801- 1810. doi:10.1111/add.15792
- 3. Wickström R. Effects of nicotine during pregnancy: human and experimental evidence. *Curr Neuropharmacol*. 2007;5(3):213-222. doi:10.2174/157015907781695955
- 4. Kubista E. [Smoking in pregnancy]. *Wien Med Wochenschr*. 1994;144(22-23):529-531.
- 5. Rumrich I, Vähäkangas K, Viluksela M, Gissler M, de Ruyter H, Hänninen O. Effects of maternal smoking on body size and proportions at birth: a register-based cohort study of 1.4 million births. *BMJ Open*. 2020;10(2):e033465. doi:10.1136/bmjopen-2019-033465
- 6. Anderson TM, Lavista Ferres JM, Ren SY, et al. Maternal Smoking Before and During Pregnancy and the Risk of Sudden Unexpected Infant Death. *Pediatrics*. 2019;143(4):e20183325. doi:10.1542/peds.2018-3325
- 7. Wehby GL, Prater K, McCarthy AM, Castilla EE, Murray JC. The Impact of Maternal Smoking during Pregnancy on Early Child Neurodevelopment. *J Hum Cap*. 2011;5(2):207-254. doi:10.1086/660885
- 8. Ino T, Shibuya T, Saito K, Ohtani T. Effects of maternal smoking during pregnancy on body composition in offspring. *Pediatr Int*. 2011;53(6):851-857. doi:10.1111/j.1442- 200X.2011.03383.x
- 9. Banderali G, Martelli A, Landi M, et al. Short and long term health effects of parental tobacco smoking during pregnancy and lactation: a descriptive review. *J Transl Med*. 2015;13:327. doi:10.1186/s12967-015-0690-y
- 10. Peacock JL, Palys TJ, Halchenko Y, et al. Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study. *BMJ Open*. 2022;12(2):e054535. doi:10.1136/bmjopen-2021-054535
- 11. LaBarre JL, Puttabyatappa M, Song PXK, et al. Maternal lipid levels across pregnancy impact the umbilical cord blood lipidome and infant birth weight. *Sci Rep*. 2020;10(1):14209. doi:10.1038/s41598-020-71081-z
- 12. Rolle-Kampczyk UE, Krumsiek J, Otto W, et al. Metabolomics reveals effects of maternal smoking on endogenous metabolites from lipid metabolism in cord blood of newborns. *Metabolomics*. 2016;12:76. doi:10.1007/s11306-016-0983-z

 13. Tan Y, Barr DB, Ryan PB, et al. High-resolution metabolomics of exposure to tobacco smoke during pregnancy and adverse birth outcomes in the Atlanta African American maternal-child cohort. *Environ Pollut*. 2022;292(Pt A):118361. doi:10.1016/j.envpol.2021.118361

- 14. Donovan MF, Cascella M. Embryology, Weeks 6-8. In: *StatPearls*. StatPearls Publishing; 2024. Accessed October 14, 2024. http://www.ncbi.nlm.nih.gov/books/NBK563181/
- 15. Huuskonen P, Keski-Nisula L, Heinonen S, et al. Kuopio birth cohort design of a Finnish joint research effort for identification of environmental and lifestyle risk factors for the wellbeing of the mother and the newborn child. *BMC Pregnancy Childbirth*. 2018;18(1):381. doi:10.1186/s12884-018-2013-9
- 16. Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. *Basic Clin Pharmacol Toxicol*. 2023;133(4):391-396. doi:10.1111/bcpt.13944
- 17. Voutilainen T, Keski-Nisula L, Rysä J, Kärkkäinen O. Parental cigarette smoking before and during pregnancy in a cohort of 21 472 pregnancies. *Basic Clin Pharmacol Toxicol*. 2024;134(4):543-555. doi:10.1111/bcpt.13987
- 18. Lehikoinen AI, Kärkkäinen OK, Lehtonen MAS, Auriola SOK, Hanhineva KJ, Heinonen ST. Alcohol and substance use are associated with altered metabolome in the first trimester serum samples of pregnant mothers. *Eur J Obstet Gynecol Reprod Biol*. 2018;223:79-84. doi:10.1016/j.ejogrb.2018.02.004
- 19. Klåvus A, Kokla M, Noerman S, et al. "notame": Workflow for Non-Targeted LC-MS Metabolic Profiling. *Metabolites*. 2020;10(4):135. doi:10.3390/metabo10040135
- 20. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics*. 2007;3(3):211-221. doi:10.1007/s11306-007-0082-2
- 21. Wishart DS, Guo A, Oler E, et al. HMDB 5.0: the Human Metabolome Database for 2022. *Nucleic Acids Res*. 2022;50(D1):D622-D631. doi:10.1093/nar/gkab1062
- 22. Tappin DM, Ford RP, Schluter PJ. Smoking during pregnancy measured by population cotinine testing. *N Z Med J*. 1997;110(1050):311-314.
- 23. Nenezic N, Kostic S, Strac DS, et al. Dehydroepiandrosterone (DHEA): Pharmacological Effects and Potential Therapeutic Application. *Mini Rev Med Chem*. 2023;23(8):941-952. doi:10.2174/1389557522666220919125817
- 24. Baron JA, Comi RJ, Cryns V, Brinck-Johnsen T, Mercer NG. The effect of cigarette smoking on adrenal cortical hormones. *J Pharmacol Exp Ther*. 1995;272(1):151-155.
- 25. Cora N, Ghandour J, Pollard CM, et al. Nicotine-induced adrenal beta-arrestin1 upregulation mediates tobacco-related hyperaldosteronism leading to cardiac dysfunction. *World J Cardiol*. 2020;12(5):192-202. doi:10.4330/wjc.v12.i5.192

26. Yan Y, Guo F, Liu K, Ding R, Wang Y. The effect of endocrine-disrupting chemicals on placental

- development. *Front Endocrinol (Lausanne)*. 2023;14:1059854.
- doi:10.3389/fendo.2023.1059854
- 27. Kenny LC, SCOPE Consortium, Brown LW, Ortea P, Tuytten R, Kell DB. Relationship between the concentration of ergothioneine in plasma and the likelihood of developing pre-eclampsia. *Biosci Rep*. 2023;43(7):BSR20230160. doi:10.1042/BSR20230160
- 28. Smith E, Ottosson F, Hellstrand S, et al. Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. *Heart*. 2020;106(9):691-697. doi:10.1136/heartjnl-2019-315485
- 29. Hinds TD, Stec DE. Bilirubin, a Cardiometabolic Signaling Molecule. *Hypertension*. 2018;72(4):788-795. doi:10.1161/HYPERTENSIONAHA.118.11130
- 30. Kodal JB, Çolak Y, Kobylecki CJ, Vedel-Krogh S, Nordestgaard BG, Afzal S. Smoking Reduces Plasma Bilirubin: Observational and Genetic Analyses in the Copenhagen General Population Study. *Nicotine Tob Res*. 2020;22(1):104-110. doi:10.1093/ntr/nty188
- 31. Kim NH, Kim HC, Lee JY, Lee JM, Suh I. Active and Passive Smoking and Serum Total Bilirubin in a Rural Korean Population. *Nicotine Tob Res*. 2016;18(5):572-579. doi:10.1093/ntr/ntv251
- 32. Weaver L, Hamoud AR, Stec DE, Hinds TD. Biliverdin reductase and bilirubin in hepatic disease. *Am J Physiol Gastrointest Liver Physiol*. 2018;314(6):G668-G676. doi:10.1152/ajpgi.00026.2018
- 33. Koh M, Ahmad I, Ko Y, et al. A short ORF-encoded transcriptional regulator. *Proc Natl Acad Sci U S A*. 2021;118(4):e2021943118. doi:10.1073/pnas.2021943118
- 34. Hamaue N. [Pharmacological role of isatin, an endogenous MAO inhibitor]. *Yakugaku Zasshi*. 2000;120(4):352-362. doi:10.1248/yakushi1947.120.4\_352
- 35. Buneeva OA, Kapitsa IG, Kazieva LS, Vavilov NE, Zgoda VG. Quantitative changes of brain isatin-binding proteins of rats with the rotenone-induced experimental parkinsonism. *Biomed Khim*. 2023;69(3):188-192. doi:10.18097/PBMC20236903188
- 36. Bowker K, Lewis S, Coleman T, Cooper S. Changes in the rate of nicotine metabolism across pregnancy: a longitudinal study. *Addiction*. 2015;110(11):1827-1832. doi:10.1111/add.13029
- 37. Qian J, Chen Q, Ward SM, Duan E, Zhang Y. Impacts of Caffeine during Pregnancy. *Trends Endocrinol Metab*. 2020;31(3):218-227. doi:10.1016/j.tem.2019.11.004
- 38. Yu T, Campbell SC, Stockmann C, et al. Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. *J Clin Pharmacol*. 2016;56(5):590-596. doi:10.1002/jcph.632
- 39. Hey E. Coffee and pregnancy. *BMJ*. 2007;334(7590):377. doi:10.1136/bmj.39122.395058.80

- 40. Jin F, Qiao C. Association of maternal caffeine intake during pregnancy with low birth weight,
- childhood overweight, and obesity: a meta-analysis of cohort studies. *Int J Obes (Lond)*.
- 2021;45(2):279-287. doi:10.1038/s41366-020-0617-4
- 41. Huffman SL, Harika RK, Eilander A, Osendarp SJM. Essential fats: how do they affect growth
- and development of infants and young children in developing countries? A literature review. *Matern Child Nutr*. 2011;7 Suppl 3(Suppl 3):44-65. doi:10.1111/j.1740-8709.2011.00356.x
- 
- 42. Jääskeläinen T, Kärkkäinen O, Jokkala J, et al. A non-targeted LC-MS metabolic profiling of
- pregnancy: longitudinal evidence from healthy and pre-eclamptic pregnancies. *Metabolomics*.
- 2021;17(2):20. doi:10.1007/s11306-020-01752-5